Article Text
Statistics from Altmetric.com
- Hepatitis B virus
- quantitative anti-HBc
- treatment response prediction
- hepetitis
- hepatitis B
- hepatitis E
- infectious disease
- hepatitis C
- hepatocellular carcinoma
- hepatoma
- hepatitis D
- liver disease in pregnancy
- genetics
- liver
We read with interest the recent article by Dandri emphasising the use of novel quantitative biomarkers as tools for predicting treatment response and disease progression in chronic hepatitis B infection (CHB).1 The authors carried out a comprehensive review of the clinical implications of quantitative measurement of viral biomarkers both in blood and in liver, such as: serum HBsAg, serum HBeAg and intrahepatic cccDNA, based on current knowledge.1 In addition to these, …
Footnotes
-
Funding Supported by grants from the National Scientific and Technological Major Project (2012ZX10002-005); and acknowledgement of Taiwan Liver Consortium for patients recruitment.
-
Competing interests P-J Chen is a consultant for Novartis and Roche. D-S Chen is a consultant for Novartis and GlaxoSmithKline. J-H Kao is a consultant for Bristol-Myers Squibb, GlaxoSmithKline, Novartis, Omrix, and Roche; and is a member of the Speaker's Bureau for Roche, Bristol-Myers Squibb, GlaxoSmithKline, and Novartis.
-
Patient consent Obtained.
-
Ethics approval This study was approved by the Ethics Committees of Zhongshan Hospital of Xiamen University.
-
Provenance and peer review Not commissioned; externally peer reviewed.